Breaking News Instant updates and real-time market news.

OPGN

OpGen

$0.59

-0.041 (-6.50%)

, TMO

Thermo Fisher

$174.86

0.73 (0.42%)

08:29
06/19/17
06/19
08:29
06/19/17
08:29

OpGen signs supply agreement to use Thermo Fisher technology to advance Acuitas

OpGen (OPGN) announced that it has entered into a global supply agreement to use Thermo Fisher Scientific's (TMO) technology to support the commercialization of its rapid molecular products and informatics system to help combat multidrug-resistant infections. OpGen will combine Thermo Fisher's real-time PCR solutions with its genomic analysis and bioinformatics technology to help healthcare providers rapidly and accurately identify bacterial antibiotic susceptibility using resistance gene profiles. Under the terms of the agreement, OpGen will commercialize the Acuitas Rapid Test for Pathogen ID and resistance genes on Thermo Fisher's new mid-throughput real-time PCR system. The effort will be supported by local labs that will be able to interpret results using customized analysis software and OpGen's cloud-based Acuitas Lighthouse Knowledgebase to match genomic analysis data with antibiotic susceptibility information to identify microbial infections in individual patients.

OPGN

OpGen

$0.59

-0.041 (-6.50%)

TMO

Thermo Fisher

$174.86

0.73 (0.42%)

OPGN OpGen
$0.59

-0.041 (-6.50%)

06/29/16
RODM
06/29/16
INITIATION
Target $2.5
RODM
Buy
OpGen initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju started OpGen with a Buy rating and $2.50 price target.
TMO Thermo Fisher
$174.86

0.73 (0.42%)

06/09/17
DBAB
06/09/17
NO CHANGE
Target $200
DBAB
Buy
Thermo Fisher price target raised to $200 from $188 at Deutsche Bank
Deutsche Bank analyst Dan Leonard raised his price target for Thermo Fisher (TMO) to $200 following his deeper look at the proposed Patheon (PTHN) acquisition. Cross-selling opportunities between the two companies do exist, but are difficult to quantify, Leonard tells investors in a research note. He keeps a Buy rating on Thermo shares.
06/09/17
LEER
06/09/17
DOWNGRADE
Target $35
LEER
Market Perform
Patheon downgraded to Market Perform from Outperform at Leerink
Leerink analyst Puneet Souda downgraded Patheon (PTHN) to Market Perform citing the pending acquisition by Thermo Fisher (TMO). The analyst does not expect antitrust concerns. He raised his price target for Patheon shares to $35 from $31.
06/08/17
JPMS
06/08/17
DOWNGRADE
Target $35
JPMS
Neutral
Patheon downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Tycho Peterson downgraded Patheon (PTHN) to Neutral citing the pending acquisition by Thermo Fisher (TMO). The analyst expects no competing bid will emerge. He raised his price target for the shares to $35 from $30.
05/19/17
05/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Bernstein initiated Nvidia (NVDA) with an Outperform and a $165 price target. 2. Cantor Fitzgerald initiated Thermo Fisher (TMO) with an Overweight rating and $194 price target. 3. Pacific Crest initiated IBM (IBM) with a Sector Weight rating. 4. Conduent (CNDT) initiated with a Market Perform rating and $18 price target at Cowen. 5. JMP Securities started coverage of Spring Bank Pharmaceuticals (SBPH) with a $20 price target and an Outperform rating. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.